Artera
Artera is a precision medicine leader leveraging AI to personalize cancer treatment. Its ArteraAI Prostate Test provides predictive and prognostic insights for prostate cancer, helping guide more effective therapy decisions.
Artera is a precision medicine company pioneering AI-driven diagnostics to personalize cancer treatment. The company’s groundbreaking ArteraAI Prostate Test is the first multimodal artificial intelligence (MMAI) biomarker test to provide both prognostic and predictive insights for patients with localized prostate cancer.
Utilizing advanced AI algorithms, the test analyzes digital biopsy images alongside clinical data to assess a patient’s prognosis and predict their response to specific therapies. Validated through multiple Phase 3 randomized trials, Artera's technology empowers clinicians to make more informed treatment decisions.
Artera operates a CLIA-certified and CAP-accredited laboratory in Jacksonville, Florida, where the ArteraAI Prostate Test is available for clinical use. Healthcare providers can conveniently order the test online at arthera.ai, making precision oncology more accessible and impactful.
